Mon, January 30, 2023
Sun, January 29, 2023
Fri, January 27, 2023
Thu, January 26, 2023

Michael Ulz Downgraded (YMAB) to Sell on, Jan 27th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. lz-downgraded-ymab-to-sell-on-jan-27th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Michael Ulz of Morgan Stanley, Downgraded "Y-mAbs Therapeutics, Inc." (YMAB) to Sell on, Jan 27th, 2023.

Michael has made no other calls on YMAB in the last 4 months.



There are 7 other peers that have a rating on YMAB. Out of the 7 peers that are also analyzing YMAB, 3 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joseph Thome of "Cowen & Co." Downgraded from Buy to Hold on, Thursday, January 5th, 2023
  • Alec Stranahan of "B of A Securities" Maintained at Hold with Increased Target to $6 on, Thursday, December 15th, 2022
  • David Nierengarten of "Wedbush" Downgraded from Buy to Hold and Held Target at $6 on, Monday, October 31st, 2022


These are the ratings of the 4 analyists that currently disagree with Michael


  • Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $12 on, Tuesday, November 1st, 2022
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, October 31st, 2022
  • Tessa Romero of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $7 on, Monday, October 31st, 2022
  • William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $27 on, Monday, October 31st, 2022

Publication Contributing Sources